Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30318569 | 0.78 | APLNR (0.44) | — | |
| SCHEMBL29907417 | 0.78 | IDO1 (0.36) | ADRA2AADRA2BADRA2C | |
| SCHEMBL25160321 | 0.78 | CCR1 (0.39) | ADRA2AADRA2BADRA2C | |
| SCHEMBL4899825 | 0.78 | IDO1 (0.36) | ADRA2AADRA2BADRA2C | |
| SCHEMBL31035754 | 0.77 | PDE9A (0.33) | PDE9A | |
| SCHEMBL20644139 | 0.74 | ADRA2A (0.41) | ADRA2AADRA2BADRA2CCA12CA1 | |
| SCHEMBL28402487 | 0.73 | ADRA2A (0.37) | ADRA2AADRA2BADRA2CCA12CA1 | |
| SCHEMBL22556951 | 0.72 | ADRA2A (0.39) | ADRA2AADRA2BADRA2CCA12CA1 | |
| SCHEMBL31676307 | 0.71 | APLNR (0.42) | — | |
| SCHEMBL19126909 | 0.71 | IDO1 (0.43) | ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528802-B2 | Heterocyclic compound | GBA2, GBA1, GALC | ADRA2A 1219/4885ADRA2B 1900/4885ADRA2C 1039/4885 |
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | ADRA2A 2928/4885ADRA2B 3841/4885ADRA2C 2960/4885 |
| US-20220274982-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | ADRA2A 2928/4885ADRA2B 3841/4885ADRA2C 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.